Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cordycepin triphosphate is the triphosphorylated form of cordycepin (3’-deoxyadenosine), a purine nucleoside analog derived from the fungus Cordyceps militaris. It is a purine ribonucleoside 5′-triphosphate and acts as an antimetabolite with antifungal, antineoplastic, antiviral, and immunomodulatory properties[2][9]. Mechanistically, cordycepin triphosphate mimics adenosine triphosphate (ATP) due to its structural similarity and can be incorporated into RNA by cellular enzymes in place of ATP. This incorporation disrupts normal RNA synthesis by inhibiting polyadenylation and acting as an RNA elongation inhibitor[2][5]. It also inhibits mTOR signaling via activation of AMP-activated protein kinase (AMPK), leading to reduced cell proliferation and induction of apoptosis in tumor cells[2][5]. The compound has been used experimentally as a transcriptional inhibitor in molecular biology assays[3], but it is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cordycepin triphosphate.